Treatment of Hypertension

        People with diabetes should be treated to achieve a blood pressure (BP) <130/80 mm Hg.
        To read this article in full you will need to make a payment

        Subscribe:

        Subscribe to Canadian Journal of Diabetes
        Already a print subscriber? Claim online access
        Already an online subscriber? Sign in
        Institutional Access: Sign in to ScienceDirect

        References

          • Adler A.I.
          • Stratton I.M.
          • Neil H.A.
          • et al.
          Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.
          BMJ. 2000; 321: 412-419
          • Schrier R.W.
          • Estacio R.O.
          • Esler A.
          • Mehler P.
          Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes.
          Kidney Int. 2002; 61: 1086-1097
          • Hansson L.
          • Zanchetti A.
          • Carruthers S.G.
          • et al.
          Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.
          Lancet. 1998; 351: 1755-1762
          • UK Prospective Diabetes Study Group
          Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.
          BMJ. 1998; 317: 703e13
          • Cushman W.C.
          • Ford C.E.
          • Cutler J.A.
          • et al.
          Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
          J Clin Hypertens. 2002; 4: 393-404
          • Lewis E.J.
          • Hunsicker L.G.
          • Clarke W.R.
          • et al.
          Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
          N Eng J Med. 2001; 345: 851-860
          • Lindholm L.
          • Ibsen J.
          • Dahlof B.
          • et al.
          Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
          Lancet. 2002; 359: 1004-1010
          • The Heart Outcomes Prevention Evaluation Study Investigators
          Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
          N Engl J Med. 2000; 342: 145-153
          • Brenner B.M.
          • Cooper M.E.
          • de Zeeuw D.
          • et al.
          The losartan renal protection study: rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).
          J Renin Angiotensin Aldosterone Syst. 2000; 1: 328-335
          • Whelton P.K.
          • Barzilay J.
          • Cushman W.C.
          • et al.
          Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
          Arch Intern Med. 2005; 165: 1401-1409
          • Weber M.A.
          • Bakris G.L.
          • Jamerson K.
          • et al.
          Cardiovascular events during differing hypertension therapies in patients with diabetes.
          J Am Coll Cardiol. 2010; 56: 77-85